Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous Sep 23 | 2021Carisma’s CT-0508 (HER2 CAR-Macrophage) Receives Fast Track Designation From the FDAAccess Free BlastFree
Posted in: Autologous, CAR-T Sep 23 | 2021Two Novel CAR-Ts for Solid Tumors Demonstrate Promising Efficacy / Activity; Are CAR-Ts More Advantageous Than Bispecific Antibodies? ESMO 2021 Day 4 – 6Access Free BlastFree
Posted in: CAR-T Sep 21 | 2021Allogene Appoints Jae Park to Their Scientific Advisory BoardAccess Free BlastFree
Posted in: Autologous, TCR Sep 20 | 2021TCR2 on Track to Identify Gavo-cel’s (Mesothelin TRuC-T) RP2D by YE 2021; Will Checkpoint Inhibitors Improve Gavo-cel’s Efficacy? ESMO 2021 Day 2Access Free BlastFree
Posted in: Autologous, CAR-T, CD19, TCR Sep 17 | 2021GSK Explores Better Patient Selection Methods for Lete-cel; Could 2seventy bio Nominate Medigene’s PRAME TCR-T as Their Second Target? Adaptimmune Presents Preclinical Data from ADP-A2M4CD8; No Updated Preclinical Results from Carisma; Tecartus Absent from CHMP Highlights; ESMO 2021 Day 1&2Access Free BlastFree
Posted in: CAR-T, CD19 Sep 16 | 2021Autolus Announces Progress with New UK Manufacturing SiteAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Sep 15 | 2021Autolus Appoints John Johnson to Their Board of DirectorsAccess Free BlastFree
Posted in: CAR-T, CD19 Sep 14 | 2021Thoughts on Novartis’s Ph3 BELINDA Trial Failure; Will Novartis Continue Pursuing Kymriah in the 2L DLBCL Setting?Access Free BlastFree
Posted in: Autologous, CAR-T, TCR Sep 14 | 2021Adaptimmune’s ADP-A2M4CD8 Has a Best Response With Ovarian Cancer Patients; Legend’s LB1901 Ph1 Trial Initiated in the USAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Sep 13 | 2021Will Tecartus Receive a Positive CHMP Opinion for R/R Adult ALL This Week? Cilta-cel Remains on Track for a November 2021 Opinion; No Mention of Breyanzi or Yescarta in September’s CHMP AgendaAccess Free BlastFree
Posted in: Allogeneic, TCR Sep 10 | 2021Adaptimmune’s Novel Gene Editing Approach; Do iPSC-derived αβT Cells Have an Advantage Over NK Cells? Thoughts on Adaptimmune’s Allogeneic Platform Virtual Event 2021Access Free BlastFree
Posted in: Allogeneic, CAR-T, TCR Sep 09 | 2021Adaptimmune Discusses Novel Engineering and Lymphodepleting Regimens During Their Allogeneic Platform Virtual Event 2021Access Free BlastFree
Posted in: Autologous, CAR-T Sep 08 | 2021bluebird & 2seventy to Split in October; Marcela Maus Appointed to 2seventy’s Board of Directors; bluebird Receives $75M in Private Equity Financing Before SeparationAccess Free BlastFree
Posted in: Allogeneic, Autologous, TCR Sep 07 | 2021Adaptimmune Partners With Genentech to Develop iPSC-derived Allogeneic TCR-TsAccess Free BlastFree
Posted in: CAR-T, CD19 Sep 03 | 2021JW Tx’s Relma-cel (JWCAR029; CD19 CAR-T) Approved in China as Benoda for ≥3L R/R LBCLAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19, TCR Sep 02 | 2021Precision Partners With Tiziana for the Use of Foralumab as a Novel Lymphodepletion Agent; How Could an Anti-CD3 Antibody Improve CAR-T Efficacy? TCR2 Tx’s Gavo-cel Receives Orphan Drug DesignationAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T Sep 01 | 2021Preliminary Results from Poseida’s P-PSMA-101 (PSMA CAR-T) Ph1 Trial in mCRPC; FDA Accepts Poseida’s P-BCMA-ALLO1 (Allogeneic BCMA CAR-T) IND in R/R MMAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, TCR Aug 27 | 2021New JNJ KLK2 CAR-T (JNJ-75229414) Ph1 Trial in mCRPC Posted; Priti Hegde Joins TCR2 Tx’s Board of DirectorsAccess Free BlastFree
Posted in: CAR-T, CD19 Aug 25 | 2021UPDATED: Indications Table for CD19 CAR-T US Approvals and SubmissionsAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.